# ![@OSTherapies Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1531707317867143171.png) @OSTherapies OS Therapies NYSE American: OSTX

OS Therapies NYSE American: OSTX posts on X about $ostx, in the, end of, ceo the most. They currently have [---] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours.

### Engagements: [---] [#](/creator/twitter::1531707317867143171/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1531707317867143171/c:line/m:interactions.svg)

- [--] Week [-----] +2.70%
- [--] Month [-----] +2,221%
- [--] Months [------] +206%
- [--] Year [------] +1,423%

### Mentions: [--] [#](/creator/twitter::1531707317867143171/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1531707317867143171/c:line/m:posts_active.svg)

- [--] Months [--] +50%
- [--] Year [--] +750%

### Followers: [---] [#](/creator/twitter::1531707317867143171/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1531707317867143171/c:line/m:followers.svg)

- [--] Week [---] +0.30%
- [--] Month [---] +4.70%
- [--] Months [---] +39%
- [--] Year [---] +216%

### CreatorRank: [---------] [#](/creator/twitter::1531707317867143171/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1531707317867143171/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  [exchanges](/list/exchanges)  [finance](/list/finance)  [countries](/list/countries)  [technology brands](/list/technology-brands)  [financial services](/list/financial-services)  [travel destinations](/list/travel-destinations) 

**Social topic influence**
[$ostx](/topic/$ostx) #1, [in the](/topic/in-the), [end of](/topic/end-of), [ceo](/topic/ceo), [rare](/topic/rare), [update](/topic/update), [health](/topic/health), [os](/topic/os), [company](/topic/company), [paul](/topic/paul)

**Top accounts mentioned or mentioned by**
[@b2idigital](/creator/undefined) [@cancernetwrk](/creator/undefined) [@benzinga](/creator/undefined) [@gcommish](/creator/undefined) [@nyse](/creator/undefined) [@onclive](/creator/undefined) [@eversana](/creator/undefined) [@eversanacompany](/creator/undefined) [@dvm360](/creator/undefined) [@sheltermetv](/creator/undefined) [@patientworthy](/creator/undefined) [@precmedonline](/creator/undefined) [@oncnewscentral](/creator/undefined) [@checkorphan](/creator/undefined) [@jlabs](/creator/undefined) [@fintechtvglobal](/creator/undefined) [@osinstitute](/creator/undefined) [@bioprocessintl](/creator/undefined) [@pharmashot](/creator/undefined) [@stbaldricks](/creator/undefined)

**Top assets mentioned**
[OS Therapies Incorporated (OSTX)](/topic/$ostx) [Johnson & Johnson (JNJ)](/topic/$jnj)
### Top Social Posts
Top posts by engagements in the last [--] hours

"The $6.4M in gross proceeds without warrants we successfully raised from our recent IPO provides us with a sufficient cash runway through mid-2025. Look out for $OSTX key data coming in Q4 2024"  
[X Link](https://x.com/OSTherapies/status/1824125679295717844)  2024-08-15T16:47Z [---] followers, [---] engagements


"( $OSTX) Our effort at Johnson & Johnson Innovation - .@JLABS is a significant step as we work to advance targeted cancer therapy. Our ADC platform technology aims to be more efficient more effective and with fewer side $JNJ #OSTX #investors https://bit.ly/3YR4Btt https://bit.ly/3YR4Btt"  
[X Link](https://x.com/OSTherapies/status/1825871255246930170)  2024-08-20T12:23Z [---] followers, [---] engagements


"$OSTX CEO Paul Romness is featured on @FintechTvGlobal sharing the journey of OS Therapies from inception to its @NYSE listing (#OSTX) and how the company's innovative technology is bringing new hope to cancer patients worldwide. #CancerResearch https://www.fintech.tv/News/Detail/8520-os-therapies-(ostx)-journey-to-being-listed-on-the-nyse-with-paul-romness https://www.fintech.tv/News/Detail/8520-os-therapies-(ostx)-journey-to-being-listed-on-the-nyse-with-paul-romness"  
[X Link](https://x.com/OSTherapies/status/1826236934873825485)  2024-08-21T12:36Z [---] followers, [---] engagements


"$OSTX CEO Paul Romness joins Proactives Steve Darling to discuss some of the companys recent accomplishments that include its prestigious acceptance into Johnson & Johnson Innovation #CancerResearch https://www.proactiveinvestors.com/companies/news/1055011/paul-romness-discusses-os-therapies-ipo-clinical-advancement-1055011.html https://www.proactiveinvestors.com/companies/news/1055011/paul-romness-discusses-os-therapies-ipo-clinical-advancement-1055011.html"  
[X Link](https://x.com/OSTherapies/status/1828877065787195804)  2024-08-28T19:27Z [---] followers, [---] engagements


".@OSTherapies $OSTXis harnessing a highly modified Listeria strain to target HER2-expressing cancer cells. Unlike the harmful strains in food contamination there is zero possibility that the OS strain could recombine with wild Listeria or cause disease. Extensively tested before human use this strain is designed to trigger a powerful immune response and is safely eliminated from the body. #cancerresearch #immuneresponse #investors #osteosarcoma #listeria https://bit.ly/3XsKZth https://bit.ly/3XsKZth"  
[X Link](https://x.com/OSTherapies/status/1835725939554050536)  2024-09-16T17:02Z [---] followers, [---] engagements


"The @OSInstitute has published the story of Lavinia the Mastiff and her battle with Osteosarcoma the leading disease killer of dogs. OS Therapies has a canine version of its osteosarcoma cancer vaccine OST-HER2 that already has conditional approval. Upon completing a small study to get full approval $OSTX aims to launch the canine vaccine into the market in [----]. Our ability to find a way to treat bone cancer in animals provides a much higher success rate for treating it in humans which OS Therapies also seeks to address. #osteosarcoma #canines #laviniathemastiff #dogs #cancervaccine #OSTX"  
[X Link](https://x.com/OSTherapies/status/1838916518060450290)  2024-09-25T12:20Z [---] followers, [---] engagements


"Thank you @NYSE We're honored to ring the Closing Bell and celebrate this exciting milestone with $OSTX now trading. Join us on our mission to develop advanced treatments for #Osteosarcoma and other solid tumors. The NYSE welcomes @OSTherapies in ringing the Closing Bell (NYSE American: $OSTX) https://t.co/JKYRdq4WxH The NYSE welcomes @OSTherapies in ringing the Closing Bell (NYSE American: $OSTX) https://t.co/JKYRdq4WxH"  
[X Link](https://x.com/OSTherapies/status/1841940274093633872)  2024-10-03T20:35Z [---] followers, [---] engagements


"Join us at the upcoming LD Micro event on 10/29 where OS Therapies (NYSE: $OSTX) CEO Paul Romness and CBO Gerald Commissiong will present a corporate overview at 11:30 AM PT. Register to watch our presentation #OSTherapies #LDMicro #InvestorConference https://ir.ostherapies.com/news-events/press-releases/detail/32/os-therapies-to-present-at-the-ld-micro-main-event-xvii https://me24.sequireevents.com/ https://ir.ostherapies.com/news-events/press-releases/detail/32/os-therapies-to-present-at-the-ld-micro-main-event-xvii https://me24.sequireevents.com/"  
[X Link](https://x.com/OSTherapies/status/1849894138889593227)  2024-10-25T19:21Z [---] followers, [---] engagements


"OS Therapies Reports First Quarter [----] Financial Results and Provides Business Update. Read the press release here: $OSTX https://bit.ly/3GY2UDv https://bit.ly/3GY2UDv"  
[X Link](https://x.com/OSTherapies/status/1923384764762874039)  2025-05-16T14:27Z [---] followers, [---] engagements


"Key takeaways on our latest announcement via @OncLive: OST-HER2 demonstrated significant improvement in 12-month EFS and favorable OS rates in a phase 2b trial for pediatric #osteosarcoma. Dive into the article here: $OSTX https://bit.ly/4jOUyvU https://bit.ly/4jOUyvU"  
[X Link](https://x.com/OSTherapies/status/1932792461253861559)  2025-06-11T13:30Z [---] followers, [---] engagements


"OS Therapies is proud to partner with @EVERSANA for the U.S. commercialization of OST-HER2 a groundbreaking immunotherapy for pediatric osteosarcoma. Together we're advancing the battle against cancer for patients. Read more: $OSTX https://pharmaphorum.com/market-access/eversana-expands-commercialisation-portfolio-os-therapies-and-iterum-therapeutics https://pharmaphorum.com/market-access/eversana-expands-commercialisation-portfolio-os-therapies-and-iterum-therapeutics"  
[X Link](https://x.com/OSTherapies/status/1934613593607024642)  2025-06-16T14:06Z [---] followers, [---] engagements


"In the news: OS Therapies teams with @EVERSANA for OST-HER2 to bring OST-HER2 to patients and families who have long awaited new options. This partnership ensures we have the infrastructure expertise and agility needed. Read via @BioProcessIntl: $OSTX https://bit.ly/4kLNCkv https://bit.ly/4kLNCkv"  
[X Link](https://x.com/OSTherapies/status/1934627192622711232)  2025-06-16T15:00Z [---] followers, [---] engagements


"Partnering w/ EVERSANA to bring OST-HER2 to pediatric osteosarcoma patients. This collab combines our innovative Listeria-based immunotherapy with EVERSANA's proven commercialization expertise. Rolling BLA submission targeted for Q3 [----]. $OSTX @Pharmashot https://bit.ly/3HFQYGZ https://bit.ly/3HFQYGZ"  
[X Link](https://x.com/OSTherapies/status/1934642329387729238)  2025-06-16T16:00Z [---] followers, [---] engagements


"OS Therapies is proud to support @StBaldricks Headshaving for a Cause event in Decatur GA. CEO Paul Romness returned to support alongside our incredible Board Member Avril McKean Dieser to support this important cause funding childhood cancer research. Thank you to all the organizers and participants $OSTX #ConquerKidsCancer #StBaldricks"  
[X Link](https://x.com/OSTherapies/status/1934643733623894041)  2025-06-16T16:06Z [---] followers, [---] engagements


"ICYMI: OS Therapies and partner @eversanacompany remain committed to helping patients facing the devastating diagnosis of cancer on the heels of U.S. commercialization of OST-HER2 in recurrent fully resected pediatric lung metastatic osteosarcoma. Eversana has activated a full scale commercialization operation and a global team of oncology experts to bring this much-needed innovation to market. This product is just the beginning of OS Therapies' impact for patients around the world. 🔗 $OSTX #Commercialization #Oncology #Osteosarcoma https://bit.ly/4jKVm4K https://bit.ly/4jKVm4K"  
[X Link](https://x.com/OSTherapies/status/1934966807997128955)  2025-06-17T13:30Z [---] followers, [---] engagements


"OS Therapies Board member Avril McKean Dieser and I rocked our new doos at the BIO International Convention in Boston this week. Shaving my head in solidarity and support of Osteosarcoma patients (for the 4th time) helps give me unbelievable strength clarity and motivation in our mission at OST"  
[X Link](https://x.com/OSTherapies/status/1936062410416062882)  2025-06-20T14:03Z [---] followers, [---] engagements


"We applaud the FDA's commitment to "reduce its reliance on randomized clinical data and seek to use more real-world evidence." Important progress for rare pediatric diseases where traditional trials present challenges. $OSTX #FDA https://bit.ly/3Id6SZw https://bit.ly/3Id6SZw"  
[X Link](https://x.com/OSTherapies/status/1937962792453116163)  2025-06-25T19:55Z [---] followers, [---] engagements


"OST-HER2 shows positive [--] year EFS improvement in the prevention or delay of recurrence in fully resected pulmonary metastatic #osteosarcoma. A new article via @CancerNetwrk highlights our recent data updates. Read more here: $OSTX https://bit.ly/45NjLDD https://bit.ly/45NjLDD"  
[X Link](https://x.com/OSTherapies/status/1940416590408712303)  2025-07-02T14:25Z [---] followers, [---] engagements


"ICYMI: OST-HER2 achieved 35% 1-year event free survival vs 20% historical control in fully resected lung metastatic #osteosarcoma patients. "The favorable safety profile of OST-HER2 compared with standard of care is also an important quality of life factor" - Dr. Robert Petit CMO Read more: $OSTX https://bit.ly/44gYz6k https://bit.ly/44gYz6k"  
[X Link](https://x.com/OSTherapies/status/1942242264849273061)  2025-07-07T15:20Z [---] followers, [---] engagements


"OST-HER2 achieves statistically significant positive 1-year EFS in pulmonary metastatic #osteosarcoma. Read more via @DDWJournal: $OSTX #RareDisease #PediatricCancer #Biotech #ClinicalTrials https://bit.ly/4nyU7Jj https://bit.ly/4nyU7Jj"  
[X Link](https://x.com/OSTherapies/status/1942640866373329292)  2025-07-08T17:44Z [---] followers, [---] engagements


"Global unity in the face of uncertainty with $OSTX CEO Paul Romness & @EVERSANAcompany VP of Business Development Farah Ahmad. Tune in to an impressive discussion during #BIO2025 about our relationship with EVERSANA as we advance clinical-stage programs: https://bit.ly/4kR4sNQ https://bit.ly/4kR4sNQ"  
[X Link](https://x.com/OSTherapies/status/1947682309706015215)  2025-07-22T15:37Z [---] followers, [---] engagements


"OST-HER2 yields statistically significant positive interim 2-year overall survival data from phase 2b #clinicaltrial in the prevention or delay of recurrent fully resected pulmonary metastatic #osteosarcoma. Read more via @CancerNetwrk: $OSTX https://bit.ly/3JbI1G6 https://bit.ly/3JbI1G6"  
[X Link](https://x.com/OSTherapies/status/1954950746945773682)  2025-08-11T16:59Z [---] followers, [---] engagements


"ICYMI: $OSTX provided stakeholders with a detailed update regarding OST-HER2 recurrent fully resected pulmonary metastatic osteosarcoma program following a highly productive End of Phase [--] Meeting with FDA. We remain on track to begin rolling BLA submission in September [----]. https://bit.ly/4mIZiVW https://bit.ly/4mIZiVW"  
[X Link](https://x.com/OSTherapies/status/1964012778437451859)  2025-09-05T17:08Z [---] followers, [---] engagements


"In a new article @dvm360 covers our veterinary divisions path forward. OS Animal Health is currently developing OST-HER2 for canine osteosarcoma using the immune-stimulatory effects of Listeria to initiate a strong immune response targeting the HER2 protein. Read here: $OSTX #Immunotherapy #AnimalHealth https://bit.ly/47Rz12V https://twitter.com/i/web/status/1991590305494176136 https://bit.ly/47Rz12V https://twitter.com/i/web/status/1991590305494176136"  
[X Link](https://x.com/OSTherapies/status/1991590305494176136)  2025-11-20T19:31Z [---] followers, [---] engagements


"OS Therapies completes final patient visit in OST-504 phase-1b prostate cancer trial. Read more via @Benzinga: $OSTX #Oncology https://bit.ly/3K6VMGx https://bit.ly/3K6VMGx"  
[X Link](https://x.com/OSTherapies/status/1966585596060602460)  2025-09-12T19:31Z [---] followers, [----] engagements


"Important read on why #osteosarcoma outcomes haven't improved in [--] years and what needs to change. Key challenges include trial feasibility biological heterogeneity inconsistent endpoints lack of biomarkers. An October [----] FDA/OSI workshop brought stakeholders together to chart a path forward. Read the full analysis: $OSTX https://bit.ly/4rNgMTY https://twitter.com/i/web/status/1998444650806300782 https://bit.ly/4rNgMTY https://twitter.com/i/web/status/1998444650806300782"  
[X Link](https://x.com/OSTherapies/status/1998444650806300782)  2025-12-09T17:28Z [---] followers, [---] engagements


"OS Therapies announced favorable FDA feedback on external control arm strategy for OST-HER2 in pediatric osteosarcoma. Read more on this news via @DrugDiscoverDev: $OSTX #PediatricOncology #Osteosarcoma https://bit.ly/3Gof9JE https://bit.ly/3Gof9JE"  
[X Link](https://x.com/OSTherapies/status/1939708037171720577)  2025-06-30T15:30Z [---] followers, [---] engagements


"New article from @pharmabiznews: OS Therapies completes patient enrolment in OST-504 phase 1b prostate cancer clinical trial. If you missed our latest announcement dive in here: $OSTX #Biotech #ClinicalResearch https://bit.ly/3VOspeC https://bit.ly/3VOspeC"  
[X Link](https://x.com/OSTherapies/status/1967647529991840161)  2025-09-15T17:51Z [---] followers, [---] engagements


"OS Therapies Chief Medical & Scientific Officer Dr. Robert Petit discusses how OST-504 is designed to harness the immune system against prostate cancer in a meaningful discussion with Cell & Gene Editor-In-Chief @ErinHarris_1. Read the article highlighting prostate cancer innovation through immunotherapy: $OSTX #CellAndGene #CGT #CellTherapyManufacturing #CancerResearch #Oncology https://bit.ly/4mJTjiN https://twitter.com/i/web/status/1973059075672846790 https://bit.ly/4mJTjiN https://twitter.com/i/web/status/1973059075672846790"  
[X Link](https://x.com/OSTherapies/status/1973059075672846790)  2025-09-30T16:15Z [---] followers, [---] engagements


"OS Therapies' OST-HER2 showed 75% overall survival at [--] years vs 40% in historical controls for pulmonary metastatic #osteosarcoma. Regulatory filings planned for UK US & EU. Read: $OSTX https://bit.ly/3IJY6mM https://bit.ly/3IJY6mM"  
[X Link](https://x.com/OSTherapies/status/1978487863625875538)  2025-10-15T15:47Z [---] followers, [---] engagements


"OST-HER2 was featured in the critically acclaimed film "Shelter Me: Cancer Pioneers" which recently won an Anthem Award and was nominated for a [----] Emmy Daytime Awards in the 'Outstanding Daytime Special' category. Congratulations to @Netflixs Black Barbie on the #DaytimeEmmys win in this category 🏆 Honored to have Shelter Me: The Cancer Pioneers alongside other remarkable winners such as @Disney. More importantly we would like to shout out 🎥 Steve Latham and his exceptional filmmaking 🔬 Dr. Nicola J. Mason her cancer research pioneering treatments for both dogs and humans with"  
[X Link](https://x.com/OSTherapies/status/1991939053034602637)  2025-11-21T18:37Z [---] followers, [---] engagements


"Proud to share that @ShelterMeTV: Cancer Pioneers featuring 🐕 canine and human patients treated with OST-HER2 has received an @anthemawards in the Documentary or Film under Awareness Categories Health category. We appreciate the clinicians partners and patient communities who helped make this work possible. ICYMI dive into our latest announcement: $OSTX #Oncology #AnthemAwards #AnimalHealth #Biotech https://bit.ly/4oQdwFJ https://twitter.com/i/web/status/1993028622739812698 https://bit.ly/4oQdwFJ https://twitter.com/i/web/status/1993028622739812698"  
[X Link](https://x.com/OSTherapies/status/1993028622739812698)  2025-11-24T18:47Z [---] followers, [---] engagements


"Successful Type C meeting with FDA regarding the Phase 2b clinical trial of OST-HER2 in recurrent fully-resected pulmonary metastatic osteosarcoma. FDA confirmed that single-arm study data in this ultra-rare pediatric cancer could support a BLA via the Accelerated Approval Program. Company reiterates end of January [----] timeline for planned BLA submission. Immune activation biomarker data expected during JP Morgan Healthcare Conference week. Read the full release: $OSTX #JPM2026 https://bit.ly/4ahVzLU https://twitter.com/i/web/status/2000572313561977303 https://bit.ly/4ahVzLU"  
[X Link](https://x.com/OSTherapies/status/2000572313561977303)  2025-12-15T14:23Z [---] followers, [---] engagements


"OS Therapies Announces Warrant Exercise Inducement & Exchange Offer. Funds already received by the Company as part of the offer extend cash runway into second half of [----]. Read the press release here: $OSTX https://bit.ly/44uhegq https://bit.ly/44uhegq"  
[X Link](https://x.com/OSTherapies/status/1937330943649313082)  2025-06-24T02:04Z [---] followers, [---] engagements


"OS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent Fully Resected Pediatric Lung Metastatic #Osteosarcoma. Read the press release: $OSTX #Immunotherapy #Biopharma https://bit.ly/4loTKPC https://bit.ly/4loTKPC"  
[X Link](https://x.com/OSTherapies/status/1937509439868928298)  2025-06-24T13:53Z [---] followers, [---] engagements


"We received positive written feedback from the FDA Type D Meeting on our regulatory pathway for Accelerated Approval of OST-HER2 in pediatric lung metastatic osteosarcoma prevention. End of Phase [--] Meeting expected Q3 [----]. ICYMI read the release: $OSTX #Immunotherapy #PediatricCancer https://bit.ly/4loTKPC https://bit.ly/4loTKPC"  
[X Link](https://x.com/OSTherapies/status/1937865922473054718)  2025-06-25T13:30Z [---] followers, [---] engagements


"OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor Osteosarcoma Conference. Read the press release here: $OSTX @AgentsMIB #MIBAgents #MakeItBetter #FACTOR2025 #F25 #Osteosarcoma https://bit.ly/44gYz6k https://bit.ly/44gYz6k"  
[X Link](https://x.com/OSTherapies/status/1939680369579590021)  2025-06-30T13:40Z [---] followers, [---] engagements


"OS Therapies announced it was granted an End of Phase [--] meeting by US FDA for OST-HER2 program in the prevention or delay of recurrent fully resected pulmonary metastatic #osteosarcoma. Read the press release: $OSTX #Oncology #Biopharma #ClinicalResearch https://bit.ly/4lF8JVK https://bit.ly/4lF8JVK"  
[X Link](https://x.com/OSTherapies/status/1940767296038809645)  2025-07-03T13:39Z [---] followers, [---] engagements


"Today OS Therapies provided a clinical and global regulatory update on its currently active clinical-stage #oncology programs. The End of Phase [--] Meeting granted by the US FDA to review the clinical data from its OST-HER2 recurrent pulmonary metastatic osteosarcoma program is scheduled for August [--] [----] during which the Company expects to seek alignment with FDA to begin a rolling review BLA submission to FDA under its Accelerated Approval Program. Read the press release for more details: $OSTX #Biotech #Immunotherapy https://bit.ly/4eLefDV https://bit.ly/4eLefDV"  
[X Link](https://x.com/OSTherapies/status/1943305271696113870)  2025-07-10T13:44Z [---] followers, [---] engagements


"Huge congrats 🎉 "@ShelterMeTV: The Cancer Pioneers" featuring OS Therapies' OST-HER2 earned [--] Daytime Emmy nominations 🏆 This film showcases the drive for new cancer treatments. Support for the film champions vital medical innovation as we advance toward BLA for OST-HER2 Watch the trailer: Stream free: $OSTX #Osteosarcoma #CancerResearch #EmmyNominated #Biotech #Immunotherapy https://to.pbs.org/4dglqTD https://bit.ly/4ki31Z6 https://twitter.com/i/web/status/1943683141962494404 https://to.pbs.org/4dglqTD https://bit.ly/4ki31Z6 https://twitter.com/i/web/status/1943683141962494404"  
[X Link](https://x.com/OSTherapies/status/1943683141962494404)  2025-07-11T14:45Z [---] followers, [---] engagements


"Today OS Therapies announced that it has closed its $4.2M warrant exercise inducement and exchange offer extending its runway through [----]. The company intends to use the net proceeds primarily to support U.S. and international regulatory and pre-commercial efforts aimed at securing accelerated marketing authorizations for OST-HER2 in the prevention or delay of recurrent fully resected pulmonary metastatic osteosarcoma. Additionally to develop further advance strategic alternatives for its OS Animal Health subsidiary close out and report on its OST-504 (previously ADXS-504) prostate cancer"  
[X Link](https://x.com/OSTherapies/status/1944759476176757089)  2025-07-14T14:02Z [---] followers, [---] engagements


"OS Therapies remains focused on our regulatory plan: End of Phase [--] Meeting with the FDA in the United States and our Scientific Advice Meetings in the United Kingdom and Europe. This delivers on our core mission of improving the treatment landscape for metastatic osteosarcoma patients. ICYMI dive into the details: $OSTX #Oncology #CancerResearch https://bit.ly/4nKYkcM https://twitter.com/i/web/status/1945121347031515176 https://bit.ly/4nKYkcM https://twitter.com/i/web/status/1945121347031515176"  
[X Link](https://x.com/OSTherapies/status/1945121347031515176)  2025-07-15T14:00Z [---] followers, [---] engagements


"In an exclusive interview with @theflynews $OSTX CEO Paul Romness discusses becoming a "commercial #biotech company by early 2026" with OST-HER2 immunotherapy for #osteosarcoma and the potential $160M+ priority review voucher. Read: #RareDisease https://bit.ly/46ndxL3 https://bit.ly/46ndxL3"  
[X Link](https://x.com/OSTherapies/status/1946204949630619710)  2025-07-18T13:46Z [---] followers, [---] engagements


"OS Therapies CEO Paul Romness on the #NYSE floor with @jonnajarian. Stay tuned $OSTX"  
[X Link](https://x.com/OSTherapies/status/1948419320540725289)  2025-07-24T16:25Z [---] followers, [----] engagements


"OS Therapies Receives Positive Feedback from UK MHRA Scientific Advice Meeting and Submits Innovative Licensing and Access Pathway (ILAP) Request for OST-HER2 in the Prevention or Delay of Recurrent Fully Resected Pulmonary Metastatic #Osteosarcoma. Read the press release: $OSTX #Immunotherapy #Biopharma https://bit.ly/4fqmYM5 https://twitter.com/i/web/status/1953449389906616392 https://bit.ly/4fqmYM5 https://twitter.com/i/web/status/1953449389906616392"  
[X Link](https://x.com/OSTherapies/status/1953449389906616392)  2025-08-07T13:33Z [---] followers, [---] engagements


"OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent Fully Resected Pulmonary Metastatic Osteosarcoma. Read more in the press release: $OSTX #Immunotherapy #Osteosarcoma #Biotech #ClinicalResearch https://bit.ly/4opJoRL https://twitter.com/i/web/status/1953449704135565464 https://bit.ly/4opJoRL https://twitter.com/i/web/status/1953449704135565464"  
[X Link](https://x.com/OSTherapies/status/1953449704135565464)  2025-08-07T13:34Z [---] followers, [---] engagements


"OS Therapies' regulatory activities for novel immunotherapy OST-HER2 are progressing. The company received positive feedback from UK MHRA Scientific Advice Meeting and submitted ILAP application for OST-HER2. MHRA suggested Project Orbis to align UK and US approval processes. EMA meeting scheduled for October [----]. More details here: $OSTX #Osteosarcoma #Biotech https://bit.ly/4fqmYM5 https://bit.ly/4fqmYM5"  
[X Link](https://x.com/OSTherapies/status/1953851998660346057)  2025-08-08T16:13Z [---] followers, [---] engagements


"OS Therapies advances regulatory pathway for OST-HER2 its immunotherapy for osteosarcoma. MHRA Scientific Advice Meeting completed EMA Scientific Advice Meeting scheduled October [----] FDA BLA submission planned for [----] Read: $OSTX #Oncology https://bit.ly/3Jbrh1M https://bit.ly/3Jbrh1M"  
[X Link](https://x.com/OSTherapies/status/1955263435941228639)  2025-08-12T13:41Z [---] followers, [---] engagements


"OS Therapies to Report Second Quarter [----] Financial Results and Provide Business Update on Tuesday August 19th [----]. Read the press release: $OSTX #BusinessUpdate https://bit.ly/47uKw0g https://bit.ly/47uKw0g"  
[X Link](https://x.com/OSTherapies/status/1956110976983449720)  2025-08-14T21:49Z [---] followers, [---] engagements


"Today OS Therapies Reports Second Quarter [----] Financial Results and Provides Business Update. U.S. FDA confirms OST-HER2 meets biological definition of Regenerative Medicine Advanced Therapy (RMAT) FDA issues OST-HER2 BLA number in preparation for Accelerated Approval submission following End of Phase [--] Meeting FDA End of Phase [--] Meeting scheduled for August [--] [----] to review Phase 2b clinical trial in the prevention or delay of recurrent pulmonary metastatic osteosarcoma Read the full press release here: $OSTX #BusinessUpdate #Immunotherapy #Biotech https://bit.ly/3V9tEEU"  
[X Link](https://x.com/OSTherapies/status/1957793376671080554)  2025-08-19T13:14Z [---] followers, [---] engagements


"OS Therapies' OST-HER2 data shows 66.6% two-year survival vs 40% historical control in Phase 2b osteosarcoma trial. First targeted immunotherapy for recurrent pulmonary metastatic osteosarcoma. Read more: $OSTX #Osteosarcoma #Biotech https://bit.ly/4mJiGSh https://bit.ly/4mJiGSh"  
[X Link](https://x.com/OSTherapies/status/1957827428841038105)  2025-08-19T15:30Z [---] followers, [---] engagements


"OS Therapies gained significant momentum in the second quarter making meaningful clinical and regulatory progress toward bringing the first new treatment for osteosarcoma to market in the US in [--] years. Statistically significant 12-month Event Free Survival and interim 2-year Overall Survival and strong safety data in Phase 2b trial drives global accelerated/conditional approval pathways. Dive into our latest update: $OSTX https://bit.ly/3V9tEEU https://twitter.com/i/web/status/1958209234149015604 https://bit.ly/3V9tEEU https://twitter.com/i/web/status/1958209234149015604"  
[X Link](https://x.com/OSTherapies/status/1958209234149015604)  2025-08-20T16:47Z [---] followers, [----] engagements


"OS Therapies regulatory update: FDA confirms OST-HER2 meets biological definition of Regenerative Medicine Advanced Therapy (RMAT) and issues BLA number in preparation for Accelerated Approval submission. End of Phase [--] Meeting scheduled August [--] [----]. Read full details: $OSTX https://bit.ly/3V9tEEU https://bit.ly/3V9tEEU"  
[X Link](https://x.com/OSTherapies/status/1958531503098315255)  2025-08-21T14:07Z [---] followers, [----] engagements


"Our CEO CEO Paul Romness & Board Member Olivia Egge join Empowered Patient Radio host @KarenJagoda to discuss #osteosarcoma a rare and aggressive form of bone cancer that primarily affects teenagers and our listeria-based #immunotherapy. Tune in: $OSTX https://bit.ly/45RaCbC https://bit.ly/45RaCbC"  
[X Link](https://x.com/OSTherapies/status/1959974467221823641)  2025-08-25T13:41Z [---] followers, [----] engagements


"OS Therapies to Provide OST-HER2 Recurrent Fully Resected Pulmonary Metastatic Osteosarcoma FDA End of Phase [--] Meeting Update on Tuesday September [--] [----]. Read the press release: $OSTX https://bit.ly/45FuCPq https://bit.ly/45FuCPq"  
[X Link](https://x.com/OSTherapies/status/1960799132014059660)  2025-08-27T20:18Z [---] followers, [----] engagements


"Reminder: OS Therapies will provide OST-HER2 recurrent fully resected pulmonary metastatic osteosarcoma FDA end of phase [--] meeting update on Tuesday September [--] [----]. $OSTX https://bit.ly/45FuCPq https://bit.ly/45FuCPq"  
[X Link](https://x.com/OSTherapies/status/1961417339263484399)  2025-08-29T13:15Z [---] followers, [---] engagements


"OS Therapies Provides OST-HER2 Recurrent Fully Resected Pulmonary Metastatic Osteosarcoma Program Update Following FDA End of Phase [--] Meeting. Company on track to begin submission of a rolling Biologics Licensing Application (BLA) request for OST-HER2 to U.S. Food & Drug Administration in September [----]. Read the press release: $OSTX #Biotech #Immunotherapy #Oncology https://bit.ly/4mIZiVW https://bit.ly/4mIZiVW"  
[X Link](https://x.com/OSTherapies/status/1962868734713872779)  2025-09-02T13:22Z [---] followers, [---] engagements


"OS Therapies is looking forward to participating in upcoming investor conferences in September [----] including: Cantor Global Healthcare Conference [----] H.C. Wainwright 27th Annual Global Investment Conference Lake Street Capital Markets 9th Annual Best Ideas Growth (BIG9) Conference Management will be available for meetings with institutional investors. Read the press release: $OSTX #Conference #BusinessUpdate https://bit.ly/4g4A7L3 https://twitter.com/i/web/status/1963225533509992662 https://bit.ly/4g4A7L3 https://twitter.com/i/web/status/1963225533509992662"  
[X Link](https://x.com/OSTherapies/status/1963225533509992662)  2025-09-03T13:00Z [---] followers, [----] engagements


"OS Therapies featured in @CancerNetwrks In The News highlighting our end of phase [--] meeting with the FDA to discuss OST-HER2 in development for our Metastatic Osteosarcoma Program. Read more: $OSTX #OncNews https://bit.ly/4p1LEix https://bit.ly/4p1LEix"  
[X Link](https://x.com/OSTherapies/status/1963324667038507106)  2025-09-03T19:34Z [---] followers, [---] engagements


"OS Therapies is participating in @HCWCO's 27th Annual Global Investment Conference kicking off today until September 10th in #NYC. A pre-recorded presentation is available for conference participants and management will be available for meetings with institutional investors. $OSTX #Conference #BusinessUpdate https://bit.ly/4g4A7L3 https://twitter.com/i/web/status/1965053499051524255 https://bit.ly/4g4A7L3 https://twitter.com/i/web/status/1965053499051524255"  
[X Link](https://x.com/OSTherapies/status/1965053499051524255)  2025-09-08T14:03Z [---] followers, [---] engagements


"OS Therapies Announces Last Patient Enrolled in OST-504 (previously ADXS-504) Phase 1b Prostate Cancer Clinical Trial Completes Last Visit. Read the press release here: $OSTX #ClinicalResearch #Biotech https://bit.ly/4mjDjE9 https://bit.ly/4mjDjE9"  
[X Link](https://x.com/OSTherapies/status/1966491840061837702)  2025-09-12T13:19Z [---] followers, [---] engagements


"OS Therapies to Participate in Spotlight Panel at #BioFuture2025 October [--] 11:00am EDT. Company management will provide an overview of OS Therapies with a particular emphasis on the clinical development and commercial plans for OST-HER2. More details can be found in the press release: $OSTX #Biotech #LifeSciences #Oncology https://bit.ly/4gwiwvC https://bit.ly/4gwiwvC"  
[X Link](https://x.com/OSTherapies/status/1969057193732239504)  2025-09-19T15:13Z [---] followers, [---] engagements


"OS Therapies CBO Gerald Commissiong will be participating in a spotlight panel "Beyond the Cure: The Brave New World of Revolutionary Cancer Therapeutics during #BioFuture2025 at @cure345 in #NewYorkCity on October [--] [----]. If youre attending and interested in setting up a meeting with executive management please send us a message. $OSTX @g_commish https://bit.ly/4gwiwvC https://bit.ly/4gwiwvC"  
[X Link](https://x.com/OSTherapies/status/1972718793169211771)  2025-09-29T17:43Z [---] followers, [---] engagements


"OS Therapies provides a regulatory update on its plans for filing marketing authorizations in the US and UK for OST-HER2 in the prevention or delay of recurrent fully resected pulmonary metastatic #osteosarcoma based on data generated from its completed Phase 2b clinical trial currently in the long term follow-up phase. Read the press release: $OSTX #Immunotherapy #Oncology #Biotech #ClinicalResearch https://bit.ly/4nWdZFh https://bit.ly/4nWdZFh"  
[X Link](https://x.com/OSTherapies/status/1973006194194432366)  2025-09-30T12:45Z [---] followers, [---] engagements


"Join Bioprocess Online Live for an in-depth conversation with leading ADC experts including OS Therapies Advisor Borys Shor Ph.D. Advisor OS Therapies. Tuesday October [--] [----] [--] AM ET Next-Gen ADCs Demand New CMC Approaches Are You Ready Register here: $OSTX #AntibodyDrugConjugates #Oncology #Biotech https://bit.ly/4mPAlaT https://bit.ly/4mPAlaT"  
[X Link](https://x.com/OSTherapies/status/1974112477093802307)  2025-10-03T14:01Z [---] followers, [---] engagements


"OS Therapies announces its participation in upcoming October [----] conferences and events. Details available in the press release: $OSTX #BusinessUpdate https://bit.ly/3KwPDUv https://bit.ly/3KwPDUv"  
[X Link](https://x.com/OSTherapies/status/1975601339544576169)  2025-10-07T16:37Z [---] followers, [---] engagements


"Today OS Therapies Advisor Borys Shor Ph.D. Advisor joined Bioprocess Online Live for an in-depth conversation with leading ADC experts to discuss antibody-drug conjugates (ADCs) that are reshaping oncology pipelines and why these innovations demand new ways of thinking across CMC. The recording is available on demand. ICYMI register here: $OSTX #Biotech #antibodydrugconjugates #Oncology https://bit.ly/4mPAlaT https://twitter.com/i/web/status/1975614660394066163 https://bit.ly/4mPAlaT https://twitter.com/i/web/status/1975614660394066163"  
[X Link](https://x.com/OSTherapies/status/1975614660394066163)  2025-10-07T17:30Z [---] followers, [---] engagements


"OS Therapies provides positive EMA regulatory update following positive rapporteur meeting. Rapporteur highlights potential broader benefits of OST-HER2 in pulmonary and primary osteosarcoma settings supported by translational canine data from the University of Pennsylvania. Read the press release: $OSTX #Biotech #Oncology https://bit.ly/48VSi41 https://bit.ly/48VSi41"  
[X Link](https://x.com/OSTherapies/status/1976278483811672350)  2025-10-09T13:28Z [---] followers, [---] engagements


"REMINDER: OS Therapies CBO Gerald Commissiong will be participating in a spotlight panel at #BioFuture2025 to discuss revolutionary cancer therapeutics alongside visionary leadership to explore breakthroughs reshaping the future of cancer therapeutics. 📅 October [--] [----] 🕐 11am ET If youre attending and interested in setting up a meeting with executive management please send us a message. $OSTX https://bit.ly/4gwiwvC https://bit.ly/4gwiwvC"  
[X Link](https://x.com/OSTherapies/status/1976350429450580150)  2025-10-09T18:13Z [---] followers, [---] engagements


"OS Therapies CEO Paul Romness and CSO Robert Petit Ph.D. join Bioprocess Onlines Better Biopharma podcast to discuss OST-HER2 a Listeria-based immunotherapy in development for osteosarcoma. Listen here: $OSTX #Biotech #Immunotherapy https://bit.ly/3KHRbLn https://bit.ly/3KHRbLn"  
[X Link](https://x.com/OSTherapies/status/1976680055062364292)  2025-10-10T16:03Z [---] followers, [---] engagements


"OS Therapies announced additional overall survival and event-free survival data generated from the Phase 2b Osteosarcoma Trial the company's 41-patient clinical trial of its off-the-shelf immunotherapeutic candidate OST-HER2 in recurrent fully resected pulmonary metastatic osteosarcoma. Read the press release: $OSTX #Osteosarcoma #Immunotherapy #Biotech https://bit.ly/3L0YlKO https://twitter.com/i/web/status/1980993335964688823 https://bit.ly/3L0YlKO https://twitter.com/i/web/status/1980993335964688823"  
[X Link](https://x.com/OSTherapies/status/1980993335964688823)  2025-10-22T13:43Z [---] followers, [---] engagements


"OS Therapies to spinoff OS Animal Health (OSAH) into standalone public company. OSAH is the company's wholly owned subsidiary developing OST-HER2 for canine osteosarcoma. The company expects OSAH to become a standalone public company on a U.S. national stock exchange in the first half of [----]. Dive into the press release for more details: $OSTX #AnimalHealth #Osteosarcoma #Immunotherapy https://bit.ly/4oQdwFJ https://bit.ly/4oQdwFJ"  
[X Link](https://x.com/OSTherapies/status/1991514690183221470)  2025-11-20T14:31Z [---] followers, [---] engagements


"OS Therapies Announces FDA PDUFA Waiver & EMA Grants Union Marketing Authorisation Eligibility. - U.S. FDA grants waiver of application fee for BLA Filing of OST-HER2. - Scheduled pre-Marketing Authorisation Application meeting with the United Kingdom's Medicines and Healthcare products Regulatory Agency on December [--] [----]. - Scheduled Type C Meeting with U.S. FDA on December [--] [----]. Read the press release: $OSTX https://bit.ly/3Y6W0RM https://bit.ly/3Y6W0RM"  
[X Link](https://x.com/OSTherapies/status/1996940432148717962)  2025-12-05T13:51Z [---] followers, [---] engagements


"For a closer look at OS Therapies approach to next-generation immunotherapy read @rareatives recent interview with CEO Paul Romness. They discuss why the company targets HER2-expressing cancers their choice of immunotherapy over other traditional cancer treatments and the science behind daznelimgene lisbac (previously OST-HER2). $OSTX #Immunotherapy #Biotech #RareDisease https://bit.ly/4oHbLd9 https://bit.ly/4oHbLd9"  
[X Link](https://x.com/OSTherapies/status/1996964229190942950)  2025-12-05T15:25Z [---] followers, [---] engagements


"OS Therapies held a successful pre-Marketing Authorisation Application with the @MHRAgovuk regarding the Phase 2b human clinical trial of OST-HER2 in the prevention or delay of recurrent fully-resected pulmonary metastatic osteosarcoma. Their perspective will be helpful as we finalize preparations for our upcoming Type C Meeting with the US FDA on Thursday December [--] [----]. Read the press release: $OSTX #Immunotherapy #Oncology #Osteosarcoma https://bit.ly/48JF88G https://bit.ly/48JF88G"  
[X Link](https://x.com/OSTherapies/status/1998403042463391855)  2025-12-09T14:43Z [---] followers, [---] engagements


"OS Therapies CBO Gerald Commissiong (@G_Commish) discusses regulatory progress for OST-HER2 immunotherapy targeting osteosarcoma. Watch the interview with @proactive_x here: https://bit.ly/44wdlHw https://bit.ly/44wdlHw"  
[X Link](https://x.com/OSTherapies/status/2000659715005559243)  2025-12-15T20:10Z [---] followers, [---] engagements


"OS Therapies' successful FDA Type C meeting for OST-HER2: FDA confirmed single-arm study data in ultra-rare pediatric cancer osteosarcoma could support BLA under Accelerated Approval Program pathway. Follow-up meeting requested once immune biomarker analysis available. Company reiterates end of January [----] BLA submission timeline. $OSTX https://bit.ly/4ahVzLU https://bit.ly/4ahVzLU"  
[X Link](https://x.com/OSTherapies/status/2000962835010998357)  2025-12-16T16:14Z [---] followers, [----] engagements


"OS Therapies Provides First Half [----] Corporate Outlook. Company finalizing preparations for end of January [----] U.S. FDA BLA submission for OST-HER2 program Phase 2b biomarker data expected during #JPM26 UK & EU regulatory filings OS Animal Health 'go-public' transaction SEC filing expected in early January [----] Read the full press release: $OSTX https://bit.ly/4pmy9c0 https://bit.ly/4pmy9c0"  
[X Link](https://x.com/OSTherapies/status/2008180789981155580)  2026-01-05T14:16Z [---] followers, [---] engagements


"OS Therapies is heading to San Francisco for the 44th Annual J.P. Morgan Healthcare Conference Jan 12-15 [----]. During #JPM26 we expect to share Phase 2b biomarker data from our OST-HER2 metastatic osteosarcoma program and discuss our planned FDA BLA submission under Accelerated Approval by the end of January with additional regulatory filings planned in the U.K. and EU. Connect with our team to learn more about our recent updates. $OSTX #JPM26 https://bit.ly/4pmy9c0 https://bit.ly/4pmy9c0"  
[X Link](https://x.com/OSTherapies/status/2009665393585967343)  2026-01-09T16:35Z [---] followers, [---] engagements


"OS Therapies provided an update outlining recent proceeds raised to provide the company with runway into [----] and are expected to support regulatory filings and commercial preparation activities related to OST-HER2 in the prevention or delay of recurrent fully resected pulmonary metastatic osteosarcoma in the U.S. UK and EU. The proceeds are also expected to provide funding for the company's wholly owned subsidiary OS Animal Health's proposed spinoff transaction preparations and general corporate purposes. Read more: $OSTX https://bit.ly/49fuAj6 https://bit.ly/49fuAj6"  
[X Link](https://x.com/OSTherapies/status/2010723076510527775)  2026-01-12T14:38Z [---] followers, [---] engagements


"#JPM26 officially begins today. OS Therapies is in San Francisco and looking forward to sharing updates on OST-HER2 including Phase 2b biomarker data expected this week and our planned FDA BLA submission later this month for metastatic osteosarcoma. Lets connect. $OSTX https://ostherapies.com/ https://ostherapies.com/"  
[X Link](https://x.com/OSTherapies/status/2010758848496242747)  2026-01-12T17:00Z [---] followers, [---] engagements


"OS Therapies announces that its subsidiary OS Animal Health has filed a Form S-1 with the SEC in preparation for an IPO. The company's focus is primarily on the re-establishment of USDA conditional approval and commercialization of OST-HER2 for osteosarcoma in canines as well as the treatment of HER2-positive cancers in animals. OS Animal Health intends to list on either the NYSE American or Nasdaq Capital Markets national stock exchange in the first half of [----]. Read more: $OSTX https://bit.ly/49Sji4p https://bit.ly/49Sji4p"  
[X Link](https://x.com/OSTherapies/status/2011441049357504562)  2026-01-14T14:11Z [---] followers, [---] engagements


"OS Therapies subsidiary OS Animal Health has filed a Form S-1 as it prepares for public listing and remains focused on reintroducing OST-HER2 for dogs with osteosarcoma backed by immune biomarker-driven results from recent studies. 🐾 Read the latest release: $OSTX $OSAH https://bit.ly/49Sji4p https://bit.ly/49Sji4p"  
[X Link](https://x.com/OSTherapies/status/2011800722879266826)  2026-01-15T14:00Z [---] followers, [---] engagements


"OS Therapies announced positive biomarker data from its Phase 2b clinical trial of OST-HER2 showing that activation of immune blood biomarkers in the interferon gamma pathway distinguished long-term from short-term survivors. This biomarker data also strengthens our pending BLA submission. Read more here: $OSTX https://bit.ly/4jKo0Vm https://bit.ly/4jKo0Vm"  
[X Link](https://x.com/OSTherapies/status/2011808695412257216)  2026-01-15T14:32Z [---] followers, [---] engagements


"OS Therapies wrapped up a meaningful #JPM26 and conversations about positive Phase 2b OST-HER2 biomarker data supporting our BLA submission and OS Animal Healths IPO filing. Thank you to everyone who connected with us during the week. Catch up on our latest updates: $OSTX https://bit.ly/4r11I43 https://bit.ly/4r11I43"  
[X Link](https://x.com/anyuser/status/2013652133862580640)  2026-01-20T16:37Z [---] followers, [---] engagements


"OS Therapies is a clinical stage oncology company and a world leader in listeria-based cancer immunotherapies. Its lead asset OST-HER2 demonstrated statistically significant benefit in the 12-month event free survival endpoint in a Phase 2b clinical trial in recurrent fully resected lung metastatic osteosarcoma. Learn more: $OSTX https://ostherapies.com/ https://ostherapies.com/"  
[X Link](https://x.com/anyuser/status/2018248151111446992)  2026-02-02T09:00Z [---] followers, [---] engagements


"New tools are helping accelerate progress in osteosarcoma research addressing an urgent unmet need. In a new @PatientWorthy feature OS Therapies outlines how artificial intelligence is being used to move beyond trial-and-error research and support more precise data-driven immunotherapy strategies. Read the feature: $OSTX https://bit.ly/4qetUQk https://bit.ly/4qetUQk"  
[X Link](https://x.com/anyuser/status/2018701194621792631)  2026-02-03T15:00Z [---] followers, [---] engagements


"On #WorldCancerDay OS Therapies recognizes the patients families clinicians and researchers working toward better outcomes in cancer care. The company is advancing new immunotherapy approaches for osteosarcoma and other solid tumors. Its lead asset OST-HER2 demonstrated statistically significant benefit in the 12-month event-free survival endpoint in a Phase 2b clinical trial in recurrent fully resected lung metastatic osteosarcoma. Learn more: $OSTX https://ostherapies.com/learn/osteosarcoma/ https://ostherapies.com/learn/osteosarcoma/"  
[X Link](https://x.com/anyuser/status/2019072243138023502)  2026-02-04T15:35Z [---] followers, [---] engagements


"Congress has passed the Mikaela Naylon Give Kids A Chance Act reauthorizing the Rare Pediatric Disease Designation Priority Review Voucher program. OS Therapies remains eligible to receive a PRV for OST-HER2 from Sept. [--] [----] to Sept. [--] [----]. Full release: $OSTX https://bit.ly/3Ze9fkj https://bit.ly/3Ze9fkj"  
[X Link](https://x.com/anyuser/status/2019116963193032937)  2026-02-04T18:32Z [---] followers, [---] engagements


"OS Therapies has initiated a BLA submission to the FDA for OST-HER2 in recurrent fully resected pulmonary metastatic osteosarcoma. This submission follows positive Phase 2b trial results showing improved 12-month event-free survival. Read more via @CancerNetwrk: $OSTX https://bit.ly/4kBGzvz https://bit.ly/4kBGzvz"  
[X Link](https://x.com/anyuser/status/2019425979416838351)  2026-02-05T15:00Z [---] followers, [---] engagements


"February is #RareDiseaseMonth. Osteosarcoma is a rare bone cancer primarily affecting children and young adults. OS Therapies is advancing OST-HER2 for this underserved population an immunotherapy with FDA Rare Pediatric Disease Designation and positive clinical data. Learn more: $OSTX https://ostherapies.com/learn/osteosarcoma/ https://ostherapies.com/learn/osteosarcoma/"  
[X Link](https://x.com/anyuser/status/2019788374618308990)  2026-02-06T15:00Z [---] followers, [---] engagements


"OST-HER2 the lead immunotherapy program from OS Therapies leverages the immune-stimulatory effects of Listeria bacteria to initiate a targeted immune response against the HER2 protein. The program has received Rare Pediatric Disease Fast Track and Orphan Drug designations from U.S. and European regulators. Explore the science: $OSTX https://ostherapies.com/ https://ostherapies.com/"  
[X Link](https://x.com/anyuser/status/2021147185207734572)  2026-02-10T09:00Z [---] followers, [---] engagements


"Today we announced that we have completed the acquisition of the listeria-based cancer immunotherapy assets of Advaxis Immunotherapies from Ayala Pharmaceuticals positioning OS Therapies as the world leader in listeria-based cancer immunotherapies. OS Therapies is a B2i Digital Featured Company. View their comprehensive profile at The acquisition significantly expands our clinical pipeline with three new cancer immunotherapy candidates: - OST-AXAL (previously AXAL/ADXS/HPV) for Human Papilloma Virus (HPV)-associated cancers (completed [--] of [--] Phase [--] trials) - OST-503 (previously ADXS-503) for"  
[X Link](https://x.com/OSTherapies/status/1910080886030434385)  2025-04-09T21:22Z [---] followers, [---] engagements


"OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent Fully-Resected Pulmonary Metastatic Osteosarcoma. Read the press release: $OSTX #Biotech #Oncology #Immunotherapy https://bit.ly/3KJhfWv https://bit.ly/3KJhfWv"  
[X Link](https://x.com/OSTherapies/status/1976630207575478709)  2025-10-10T12:45Z [---] followers, [---] engagements


"New from @OncLive: OST-HER2 Displays Potential OS Benefit in Recurrent Fully Resected Pulmonary Metastatic Osteosarcoma. Dive into the key takeaways: $OSTX #Oncology #Biotech https://bit.ly/3KORow9 https://bit.ly/3KORow9"  
[X Link](https://x.com/OSTherapies/status/1976700025712349220)  2025-10-10T17:23Z [---] followers, [---] engagements


"$OSTX - Here is a link to today's investor update conference call for Monday October [--] [----] at 8:30am ET: https://ir.ostherapies.com/news-events/ir-calendar/detail/20251013-investor-conference-call https://ir.ostherapies.com/news-events/ir-calendar/detail/20251013-investor-conference-call"  
[X Link](https://x.com/OSTherapies/status/1977702937229980055)  2025-10-13T11:48Z [---] followers, [----] engagements


"Insightful discussions on the future of revolutionary cancer therapeutics at #BioFuture2025 with CBO @g_commish. $OSTX"  
[X Link](https://x.com/OSTherapies/status/1978187660398059955)  2025-10-14T19:54Z [---] followers, [---] engagements


"OS Therapies Granted Final Type C Meeting by U.S. FDA and pre-MAA Meeting by U.K. MHRA for OST-HER2 in the Prevention or Delay of Recurrent Fully Resected Pulmonary Metastatic #Osteosarcoma. Read the press release: $OSTX #Immunotherapy #Biotech https://bit.ly/46ZDBfa https://bit.ly/46ZDBfa"  
[X Link](https://x.com/OSTherapies/status/1979179853199950288)  2025-10-17T13:37Z [---] followers, [---] engagements


"Today's the day 🎬✨"Shelter Me: Cancer Pioneers" is nominated for [--] #DaytimeEmmys Awards at the 52nd Annual Emmys in Pasadena. 🎬 Watch the trailer: $OSTX @TheEmmys https://www.youtube.com/watchv=z2YLhT3bb1Q https://www.youtube.com/watchv=z2YLhT3bb1Q"  
[X Link](https://x.com/OSTherapies/status/1979239041251135820)  2025-10-17T17:32Z [---] followers, [---] engagements


"🤝 #DaytimeEmmys available on TV or livestream: $OSTX https://watch.theemmys.tv/ https://watch.theemmys.tv/"  
[X Link](https://x.com/OSTherapies/status/1979239130627461277)  2025-10-17T17:32Z [---] followers, [---] engagements


"ICYMI: OS Therapies reported positive final 2-year OS data from its Phase 2b OST-HER2 trial in metastatic osteosarcoma 75% vs 40% in historical controls (p 0.0001). Meetings with MHRA FDA & EMA planned for Dec. [----]. Read more: $OSTX #Biotech #Oncology https://bit.ly/3KJhfWv https://bit.ly/3KJhfWv"  
[X Link](https://x.com/OSTherapies/status/1980662217402970258)  2025-10-21T15:47Z [---] followers, [---] engagements


"A new @dvm360 article covers how OST-HER2's canine trials are paving the way for human #osteosarcoma treatment. Canine and human osteosarcoma are 99% genetically identical. Comparative #oncology accelerating breakthroughs. $OSTX https://bit.ly/42Q4O1c https://bit.ly/42Q4O1c"  
[X Link](https://x.com/OSTherapies/status/1980706851353244035)  2025-10-21T18:44Z [---] followers, [---] engagements


"In a recent @SPGlobal article head of animal health @JHJournalist spoke to CEO Paul Romness to discuss the companys development of OST-HER2 an immunotherapy targeting HER2-expressing osteosarcoma cells in dogs. The interview is available below. $OSTX #Biotech #Immunotherapy #CanineTherapy #Osteosarcoma https://twitter.com/i/web/status/1981028036414771483 https://twitter.com/i/web/status/1981028036414771483"  
[X Link](https://x.com/OSTherapies/status/1981028036414771483)  2025-10-22T16:01Z [---] followers, [---] engagements


"$OSTX is at the Maxim Growth Summit today in NYC. Chairman & CEO Paul Romness and CBO Gerald Commissiong are presenting and available for one-on-one meetings. #MaximGrowthSummit2025"  
[X Link](https://x.com/OSTherapies/status/1981031511215177762)  2025-10-22T16:14Z [---] followers, [---] engagements


"Following a successful Phase [--] Meeting with the FDA $OSTX recently announced a second Type C Meeting to support a BLA under the Accelerated Approval Program. https://bit.ly/4qoujRo https://bit.ly/4qoujRo"  
[X Link](https://x.com/OSTherapies/status/1981045368256110915)  2025-10-22T17:09Z [---] followers, [---] engagements


"ICYMI: $OSTX reported 73.8% 2-year OS for patients with a lung-only first metastatic event vs. 30% Natural History Comparator (p 0.0001). Meetings with MHRA FDA & EMA expected in Dec. [----]. Learn more about the results: https://bit.ly/3L0YlKO https://bit.ly/3L0YlKO"  
[X Link](https://x.com/OSTherapies/status/1981784498996953416)  2025-10-24T18:06Z [---] followers, [---] engagements


"OS Therapies is at #BIOEurope in Vienna Austria November 3-5 [----]. Chairman & CEO Paul Romness is participating in one-on-one meetings. If youre attending send us a message to connect and set up a meeting. $OSTX"  
[X Link](https://x.com/OSTherapies/status/1985378416124670426)  2025-11-03T16:07Z [---] followers, [---] engagements


"Our advisor Dr. Borys Shor joined industry leaders at Bioprocess Online Live to discuss next-gen ADC development. Key insights on linker innovations site-specific conjugation and navigating complex CMC strategies for advanced therapeutics. $OSTX Read the full feature: #Biotech https://bit.ly/49GxAFA https://bit.ly/49GxAFA"  
[X Link](https://x.com/OSTherapies/status/1985735334378819711)  2025-11-04T15:46Z [---] followers, [---] engagements


"Data from $OSTX Phase 2b trial reveal OST-HER2's broad efficacy across osteosarcoma patient subgroups: ✓ 50% 1-year EFS in 2nd+ metastatic events ✓ Favorable safety vs chemotherapy ✓ Representative patient recruitment Read the details: https://bit.ly/3L0YlKO https://bit.ly/3L0YlKO"  
[X Link](https://x.com/OSTherapies/status/1986844538439110842)  2025-11-07T17:13Z [---] followers, [---] engagements


"New #InVivo feature: OS Therapies Eyes Mid [----] Launch After Breakthrough Results for #Osteosarcoma Immunotherapy. Subscribe @INVIVOnow for full access: $OSTX #Biotech #Oncology https://bit.ly/4p5QkD3 https://bit.ly/4p5QkD3"  
[X Link](https://x.com/OSTherapies/status/1987948779723493448)  2025-11-10T18:21Z [---] followers, [---] engagements


"OS Therapies Reports Third Quarter [----] Financial Results and Provides Business Update. Read the press release: $OSTX https://bit.ly/44cMnnW https://bit.ly/44cMnnW"  
[X Link](https://x.com/OSTherapies/status/1990420792396455983)  2025-11-17T14:04Z [---] followers, [---] engagements


"OS Therapies receives non-proprietary name 'daznelimgene lisbac' for OST-HER2 from the International Nonproprietary Names Expert Committee of @WHO marking a milestone on our path towards gaining regulatory approval. Read the press release: $OSTX #Oncology #immunotherapy https://twitter.com/i/web/status/1993331654681653615 https://bit.ly/4oaqahv https://twitter.com/i/web/status/1993331654681653615 https://bit.ly/4oaqahv"  
[X Link](https://x.com/OSTherapies/status/1993331654681653615)  2025-11-25T14:51Z [---] followers, [---] engagements


"OS Animal Health is set to spin off as a standalone public company in [----] advancing canine OST-HER2 previously conditionally approved by the USDA for canine osteosarcoma. ICYMI dive into the feature via @tvbpublication: $OSTX #AnimalHealth #Oncology https://bit.ly/4oYqdOH https://bit.ly/4oYqdOH"  
[X Link](https://x.com/OSTherapies/status/1993700081950736487)  2025-11-26T15:15Z [---] followers, [---] engagements


"OS Therapies CEO Paul Romness connects with WMKV's Health Scope to talk all things innovation in osteosarcoma treatment our projected [----] timeline to FDA and MAA filing and why we are driven to develop oncology immunotherapies. Listen now 👉 $OSTX #Immunotherapy #Oncology https://bit.ly/48QJMmm https://bit.ly/48QJMmm"  
[X Link](https://x.com/OSTherapies/status/1996643464956547466)  2025-12-04T18:11Z [---] followers, [---] engagements


"OST-HER2 Phase 2b trial confirms predictive immune biomarkers in human metastatic osteosarcoma. Data supports upcoming BLA submission. Learn more: $OSTX https://bit.ly/4jKo0Vm https://bit.ly/4jKo0Vm"  
[X Link](https://x.com/anyuser/status/2012172956286292119)  2026-01-16T14:39Z [---] followers, [---] engagements


"Results show that biomarkers trained on canine metastatic osteosarcoma data were predictive of clinical outcomes in OS Therapies human Phase 2b OSTHER2 trial. Learn more from our latest announcement: $OSTX https://bit.ly/4jKo0Vm https://bit.ly/4jKo0Vm"  
[X Link](https://x.com/anyuser/status/2013974967298281559)  2026-01-21T14:00Z [---] followers, [---] engagements


"OS Therapies plans to seek FDA UK and EU approval for OST-HER2 a cancer vaccine targeting recurrent metastatic osteosarcoma. New Phase IIb biomarker data supports the companys regulatory strategy. Read more from @PrecMedOnline: $OSTX https://bit.ly/3YKxjLo https://bit.ly/3YKxjLo"  
[X Link](https://x.com/anyuser/status/2014352512078250076)  2026-01-22T15:00Z [---] followers, [---] engagements


"Positive Phase 2b results for OS Therapies OST-HER2 immunotherapy strengthen regulatory filings with the FDA and set a path for U.K. U.S. and European approval later in [----]. Read the coverage from @Benzinga: $OSTX https://bit.ly/49K8MuN https://bit.ly/49K8MuN"  
[X Link](https://x.com/anyuser/status/2014714904788259059)  2026-01-23T15:00Z [---] followers, [---] engagements


"Positive biomarker data from OS Therapies Phase 2b OST-HER2 trial shows interferon gamma pathway activation predicts overall survival in pulmonary metastatic osteosarcoma. Read more from @OncNewsCentral: $OSTX https://bit.ly/4qy1S39 https://bit.ly/4qy1S39"  
[X Link](https://x.com/anyuser/status/2015802055479226555)  2026-01-26T15:00Z [---] followers, [---] engagements


"OS Therapies initiated US FDA BLA submission for OST-HER2 and plans to engage in a Type D meeting with the FDA to review new comparative oncology biomarker data. Read more here: $OSTX https://bit.ly/3NTKozN https://bit.ly/3NTKozN"  
[X Link](https://x.com/anyuser/status/2018331944715505919)  2026-02-02T14:33Z [---] followers, [---] engagements


"With OST-HER2 BLA submission underway OS Therapies remains on track for Rare Pediatric Disease Designation eligibility and potential Priority Review Voucher. Read more: $OSTX https://bit.ly/3NTKozN https://bit.ly/3NTKozN"  
[X Link](https://x.com/anyuser/status/2019063604817829958)  2026-02-04T15:00Z [---] followers, [---] engagements


"CEO Spotlight: There is strong demand for compassionate use of OST-HER2 from the patient community underscoring the urgent need for new therapies in Human Metastatic Osteosarcoma says OS Therapies CEO Paul Romness as OST-HER2 BLA submission progresses with FDA. Get the details: $OSTX https://bit.ly/3NTKozN https://bit.ly/3NTKozN"  
[X Link](https://x.com/anyuser/status/2021600267473387864)  2026-02-11T15:00Z [---] followers, [---] engagements


"This #RareDiseaseMonth we reflect on the need for better options for the patients and families affected by osteosarcoma each year in the U.S. OS Therapies is advancing OST-HER2 an immunotherapy with Rare Pediatric Disease Fast-Track and Orphan Drug designations and positive Phase 2b data. Learn about this work: $OSTX https://bit.ly/4jqxWSg https://bit.ly/4jqxWSg"  
[X Link](https://x.com/anyuser/status/2021962640113779090)  2026-02-12T15:00Z [---] followers, [---] engagements


"Policy can directly shape how quickly new therapies reach children with rare cancers. The reauthorization of the Pediatric PRV program through the Mikaela Naylon Give Kids A Chance Act strengthens incentives for research regulatory progress and access to emerging treatments. Dive into how this legislation supports ongoing work in osteosarcoma and future pipeline development at OS Therapies: $OSTX https://bit.ly/3Ze9fkj https://bit.ly/3Ze9fkj"  
[X Link](https://x.com/anyuser/status/2022342822288912496)  2026-02-13T16:11Z [---] followers, [--] engagements


"New podcast 🎙 CEO Paul Romness joins Cell & Gene: The Podcast to share how OS Therapies is tackling pulmonary metastatic osteosarcoma with a HER2-targeted immunotherapy approach and insights from a recent Phase 2B trial. Listen here with a free subscription or on your favorite podcast platform: $OSTX https://bit.ly/4csuM0i https://bit.ly/4csuM0i"  
[X Link](https://x.com/anyuser/status/2022362717303067034)  2026-02-13T17:30Z [---] followers, [---] engagements


"On International Childhood Cancer Day we recognize children and families facing osteosarcoma and other rare cancers. OS Therapies is empowered to continue its groundbreaking work combating osteosarcoma where there is still significant unmet need for patients - primarily children and teens. $OSTX #ICCD"  
[X Link](https://x.com/anyuser/status/2023049746877653141)  2026-02-15T15:00Z [---] followers, [--] engagements


"New podcast 🎙 CEO Paul Romness joins Cell & Gene: The Podcast to share how OS Therapies is tackling pulmonary metastatic osteosarcoma with a HER2-targeted immunotherapy approach and insights from a recent Phase 2B trial. Listen here with a free subscription or on your favorite podcast platform: $OSTX https://bit.ly/4csuM0i https://bit.ly/4csuM0i"  
[X Link](https://x.com/anyuser/status/2022362717303067034)  2026-02-13T17:30Z [---] followers, [---] engagements


"Policy can directly shape how quickly new therapies reach children with rare cancers. The reauthorization of the Pediatric PRV program through the Mikaela Naylon Give Kids A Chance Act strengthens incentives for research regulatory progress and access to emerging treatments. Dive into how this legislation supports ongoing work in osteosarcoma and future pipeline development at OS Therapies: $OSTX https://bit.ly/3Ze9fkj https://bit.ly/3Ze9fkj"  
[X Link](https://x.com/anyuser/status/2022342822288912496)  2026-02-13T16:11Z [---] followers, [--] engagements


"This #RareDiseaseMonth we reflect on the need for better options for the patients and families affected by osteosarcoma each year in the U.S. OS Therapies is advancing OST-HER2 an immunotherapy with Rare Pediatric Disease Fast-Track and Orphan Drug designations and positive Phase 2b data. Learn about this work: $OSTX https://bit.ly/4jqxWSg https://bit.ly/4jqxWSg"  
[X Link](https://x.com/anyuser/status/2021962640113779090)  2026-02-12T15:00Z [---] followers, [---] engagements


"CEO Spotlight: There is strong demand for compassionate use of OST-HER2 from the patient community underscoring the urgent need for new therapies in Human Metastatic Osteosarcoma says OS Therapies CEO Paul Romness as OST-HER2 BLA submission progresses with FDA. Get the details: $OSTX https://bit.ly/3NTKozN https://bit.ly/3NTKozN"  
[X Link](https://x.com/anyuser/status/2021600267473387864)  2026-02-11T15:00Z [---] followers, [---] engagements


"OST-HER2 the lead immunotherapy program from OS Therapies leverages the immune-stimulatory effects of Listeria bacteria to initiate a targeted immune response against the HER2 protein. The program has received Rare Pediatric Disease Fast Track and Orphan Drug designations from U.S. and European regulators. Explore the science: $OSTX https://ostherapies.com/ https://ostherapies.com/"  
[X Link](https://x.com/anyuser/status/2021147185207734572)  2026-02-10T09:00Z [---] followers, [---] engagements


"February is #RareDiseaseMonth. Osteosarcoma is a rare bone cancer primarily affecting children and young adults. OS Therapies is advancing OST-HER2 for this underserved population an immunotherapy with FDA Rare Pediatric Disease Designation and positive clinical data. Learn more: $OSTX https://ostherapies.com/learn/osteosarcoma/ https://ostherapies.com/learn/osteosarcoma/"  
[X Link](https://x.com/anyuser/status/2019788374618308990)  2026-02-06T15:00Z [---] followers, [---] engagements


"OS Therapies has initiated a BLA submission to the FDA for OST-HER2 in recurrent fully resected pulmonary metastatic osteosarcoma. This submission follows positive Phase 2b trial results showing improved 12-month event-free survival. Read more via @CancerNetwrk: $OSTX https://bit.ly/4kBGzvz https://bit.ly/4kBGzvz"  
[X Link](https://x.com/anyuser/status/2019425979416838351)  2026-02-05T15:00Z [---] followers, [---] engagements


"Congress has passed the Mikaela Naylon Give Kids A Chance Act reauthorizing the Rare Pediatric Disease Designation Priority Review Voucher program. OS Therapies remains eligible to receive a PRV for OST-HER2 from Sept. [--] [----] to Sept. [--] [----]. Full release: $OSTX https://bit.ly/3Ze9fkj https://bit.ly/3Ze9fkj"  
[X Link](https://x.com/anyuser/status/2019116963193032937)  2026-02-04T18:32Z [---] followers, [---] engagements


"On #WorldCancerDay OS Therapies recognizes the patients families clinicians and researchers working toward better outcomes in cancer care. The company is advancing new immunotherapy approaches for osteosarcoma and other solid tumors. Its lead asset OST-HER2 demonstrated statistically significant benefit in the 12-month event-free survival endpoint in a Phase 2b clinical trial in recurrent fully resected lung metastatic osteosarcoma. Learn more: $OSTX https://ostherapies.com/learn/osteosarcoma/ https://ostherapies.com/learn/osteosarcoma/"  
[X Link](https://x.com/anyuser/status/2019072243138023502)  2026-02-04T15:35Z [---] followers, [---] engagements


"With OST-HER2 BLA submission underway OS Therapies remains on track for Rare Pediatric Disease Designation eligibility and potential Priority Review Voucher. Read more: $OSTX https://bit.ly/3NTKozN https://bit.ly/3NTKozN"  
[X Link](https://x.com/anyuser/status/2019063604817829958)  2026-02-04T15:00Z [---] followers, [---] engagements


"New tools are helping accelerate progress in osteosarcoma research addressing an urgent unmet need. In a new @PatientWorthy feature OS Therapies outlines how artificial intelligence is being used to move beyond trial-and-error research and support more precise data-driven immunotherapy strategies. Read the feature: $OSTX https://bit.ly/4qetUQk https://bit.ly/4qetUQk"  
[X Link](https://x.com/anyuser/status/2018701194621792631)  2026-02-03T15:00Z [---] followers, [---] engagements


"OS Therapies initiated US FDA BLA submission for OST-HER2 and plans to engage in a Type D meeting with the FDA to review new comparative oncology biomarker data. Read more here: $OSTX https://bit.ly/3NTKozN https://bit.ly/3NTKozN"  
[X Link](https://x.com/anyuser/status/2018331944715505919)  2026-02-02T14:33Z [---] followers, [---] engagements


"OS Therapies is a clinical stage oncology company and a world leader in listeria-based cancer immunotherapies. Its lead asset OST-HER2 demonstrated statistically significant benefit in the 12-month event free survival endpoint in a Phase 2b clinical trial in recurrent fully resected lung metastatic osteosarcoma. Learn more: $OSTX https://ostherapies.com/ https://ostherapies.com/"  
[X Link](https://x.com/anyuser/status/2018248151111446992)  2026-02-02T09:00Z [---] followers, [---] engagements


"Positive biomarker data from OS Therapies Phase 2b OST-HER2 trial shows interferon gamma pathway activation predicts overall survival in pulmonary metastatic osteosarcoma. Read more from @OncNewsCentral: $OSTX https://bit.ly/4qy1S39 https://bit.ly/4qy1S39"  
[X Link](https://x.com/anyuser/status/2015802055479226555)  2026-01-26T15:00Z [---] followers, [---] engagements


"Positive Phase 2b results for OS Therapies OST-HER2 immunotherapy strengthen regulatory filings with the FDA and set a path for U.K. U.S. and European approval later in [----]. Read the coverage from @Benzinga: $OSTX https://bit.ly/49K8MuN https://bit.ly/49K8MuN"  
[X Link](https://x.com/anyuser/status/2014714904788259059)  2026-01-23T15:00Z [---] followers, [---] engagements


"OS Therapies plans to seek FDA UK and EU approval for OST-HER2 a cancer vaccine targeting recurrent metastatic osteosarcoma. New Phase IIb biomarker data supports the companys regulatory strategy. Read more from @PrecMedOnline: $OSTX https://bit.ly/3YKxjLo https://bit.ly/3YKxjLo"  
[X Link](https://x.com/anyuser/status/2014352512078250076)  2026-01-22T15:00Z [---] followers, [---] engagements


"Results show that biomarkers trained on canine metastatic osteosarcoma data were predictive of clinical outcomes in OS Therapies human Phase 2b OSTHER2 trial. Learn more from our latest announcement: $OSTX https://bit.ly/4jKo0Vm https://bit.ly/4jKo0Vm"  
[X Link](https://x.com/anyuser/status/2013974967298281559)  2026-01-21T14:00Z [---] followers, [---] engagements


"OS Therapies wrapped up a meaningful #JPM26 and conversations about positive Phase 2b OST-HER2 biomarker data supporting our BLA submission and OS Animal Healths IPO filing. Thank you to everyone who connected with us during the week. Catch up on our latest updates: $OSTX https://bit.ly/4r11I43 https://bit.ly/4r11I43"  
[X Link](https://x.com/anyuser/status/2013652133862580640)  2026-01-20T16:37Z [---] followers, [---] engagements


"OST-HER2 Phase 2b trial confirms predictive immune biomarkers in human metastatic osteosarcoma. Data supports upcoming BLA submission. Learn more: $OSTX https://bit.ly/4jKo0Vm https://bit.ly/4jKo0Vm"  
[X Link](https://x.com/anyuser/status/2012172956286292119)  2026-01-16T14:39Z [---] followers, [---] engagements

### Topic Creators

https://lunarcrush.com/api4/public/topic/:topic/creators/v1

Get the top creators for a social topic

input parameters:

+ **topic**: _Provide the topic to get details for. A topic must be all lower case and can only include letters, numbers, spaces, # and $._ **required**

Example request:

```bash
curl -H "Authorization: Bearer <API_KEY>" https://lunarcrush.com/api4/public/topic/bitcoin/creators/v1
```



Example response:

```json
{
  "data": [
    {
      "creator_id": "twitter::1605310254085980161",
      "creator_name": "Bitcoin_Teddy",
      "creator_avatar": "https://pbs.twimg.com/profile_images/1739753415134138368/FrWHMAnb_200x200.jpg",
      "creator_followers": 74293,
      "creator_rank": 1,
      "interactions_24h": [-------]
    }
  ]
}
```

Schema:

+ **creator_id**: The [network]::[unique_id] for the influencer
+ **creator_name**: The unique screen name for the influencer
+ **creator_avatar**: The URL to the avatar for the creator
+ **creator_followers**: number of followers the account has
+ **creator_rank**: ranking based on all posts in the last [--] hours that have interactions
+ **interactions_24h**: Number of interactions in the last [--] hours




---

### Creators List

https://lunarcrush.com/api4/public/creators/list/v1

Get a list of trending social creators over all of social based on interactions. To get lists of creators by category or topic see the topics and categories endpoints.

Example request:

```bash
curl -H "Authorization: Bearer <API_KEY>" https://lunarcrush.com/api4/public/creators/list/v1
```



Example response:

```json
{
  "data": [
    {
      "creator_name": "elonmusk",
      "creator_display_name": "Elon Musk",
      "creator_id": "44196397",
      "creator_network": "twitter",
      "creator_avatar": "https://pbs.twimg.com/profile_images/2008546467615580160/57KcqsTA_200x200.jpg",
      "creator_followers": 234295750,
      "creator_posts": 3649,
      "creator_rank": 1,
      "interactions_24h": [---------]
    }
  ]
}
```

Schema:

+ **creator_name**: The unique screen name for the influencer
+ **creator_display_name**: The chosen display name for the influencer if available
+ **creator_id**: The [network]::[unique_id] for the influencer
+ **creator_network**: The social network for the post or influencer. We still refer to x as twitter out of developer preference.
+ **creator_avatar**: The URL to the avatar for the creator
+ **creator_followers**: number of followers the account has
+ **creator_posts**: total number of posts with interactions in the last [--] hours
+ **creator_rank**: ranking based on all posts in the last [--] hours that have interactions
+ **interactions_24h**: Number of interactions in the last [--] hours




---

### Creator

https://lunarcrush.com/api4/public/creator/:network/:id/v1

Get detail information on a specific creator

input parameters:

+ **network**: _Provide the network for the creator. One of twitter, youtube, instagram, reddit, or tiktok_ **required**
+ **id**: _Provide the unique ID or screen name of the creator_ **required**

Example request:

```bash
curl -H "Authorization: Bearer <API_KEY>" https://lunarcrush.com/api4/public/creator/twitter/elonmusk/v1
```



Example response:

```json
{
  "data": {
    "creator_id": "twitter::44196397",
    "creator_name": "elonmusk",
    "creator_display_name": "Elon Musk",
    "creator_avatar": "https://pbs.twimg.com/profile_images/2008546467615580160/57KcqsTA_200x200.jpg",
    "creator_followers": 234296337,
    "creator_rank": 2,
    "interactions_24h": 318539577,
    "topic_influence": [
      {
        "topic": "in the",
        "count": 294,
        "percent": 5.88,
        "rank": [--]
      }
    ],
    "top_community": [
      {
        "creator_name": "grok",
        "creator_display_name": "Grok",
        "creator_avatar": "https://pbs.twimg.com/profile_images/1893219113717342208/Vgg2hEPa_200x200.jpg",
        "count": [---]
      }
    ]
  }
}
```

Schema:

+ **creator_id**: The [network]::[unique_id] for the influencer
+ **creator_name**: The unique screen name for the influencer
+ **creator_display_name**: The chosen display name for the influencer if available
+ **creator_avatar**: The URL to the avatar for the creator
+ **creator_followers**: number of followers the account has
+ **creator_rank**: ranking based on all posts in the last [--] hours that have interactions
+ **interactions_24h**: Number of interactions in the last [--] hours
+ **topic_influence**: an array of social topics and the creators ranking on each topic
+ **topic**: LunarCrush social topic. Can only includes letters, numbers, spaces, #, and $
+ **top_community**: an array of the top accounts that have recently mentioned this creator or that this creator has mentioned




---

### Creator Time Series

https://lunarcrush.com/api4/public/creator/:network/:id/time-series/v1

Get time series data on a creator.

input parameters:

+ **network**: _Influencer social network_ **required**
+ **id**: _The unique id or screen name of the creator_ **required**
+ **bucket**: _bucket time series data into hours or days. default is hours._ 
+ **interval**: _Use interval to specify the start and end time automatically for convenience. If "start" or "end" parameters are provided this parameter is ignored._ 
+ **start**: _The start time (unix timestamp) to go back to._ 
+ **end**: _The end time (unix timestamp) to stop at._ 

Example request:

```bash
curl -H "Authorization: Bearer <API_KEY>" https://lunarcrush.com/api4/public/creator/twitter/lunarcrush/time-series/v1
```



Example response:

```json
{
  "config": {
    "network": "twitter",
    "influencer_id": "twitter::988992203568562176",
    "interval": "1w",
    "start": 1769990400,
    "end": 1770681600,
    "bucket": "hour",
    "name": "lunarcrush",
    "remote_api": "danode1-13",
    "generated": [----------]
  },
  "data": [
    {
      "time": 1769990400,
      "followers": 305326,
      "interactions": 717,
      "posts_active": 14,
      "creator_rank": [------]
    }
  ]
}
```

Schema:

+ **config**: This includes the inputs for the request processed by the server and may include additional hints about the request and response information.
+ **network**: The social network for the post or influencer. We still refer to x as twitter out of developer preference.
+ **interval**: Typically used for specifying time intervals like 1w = [--] week, 1m = [--] month etc
+ **start**: Start/from unix timestamp (in seconds)
+ **end**: End/to unix timestamp (in seconds)
+ **bucket**: Data is generally bucketed into hours or days
+ **name**: The full name of the asset
+ **generated**: A unix timestamp (in seconds) when the data was generated to understand possibly stale data
+ **time**: A unix timestamp (in seconds)
+ **followers**: The number of publicly displayed followers the creator has
+ **interactions**: number of all publicly measurable interactions on a social post (views, likes, comments, thumbs up, upvote, share etc)
+ **posts_active**: number of unique social posts with interactions
+ **creator_rank**: ranking based on all posts in the last [--] hours that have interactions




---

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing